The era of Big Data is upon us. Advances in technology allow us not only to capture and store more data but also at lower cost than before. In healthcare and the life sciences, data is being amassed by the petabyte (that’s 1,000 terabytes) from microarrays to high-throughput sequencing, drug compound libraries, and patient data.
With so much data being generated, coupled with the advent of cloud computing and business analytics, the commercial potential of Big Data is approaching an inflection point in the life sciences.
But what exactly is this oft-hyped term, “Big Data”? To businessmen, Big Data is a tool used to understand and reach more consumers via “smart” advertising. To biologists, Big Data is a fuzzy term alluding somewhat to genomic sequencing. To the data scientist, it may be about analyzing and seeing patterns and trends in large parcels of data. Whichever it is, Big Data has the potential to have a major impact on our daily lives and it is this key point that makes the commercialization of Big Data that appealing.
Globally, the commercial potential of Big Data has attracted many investors and entrepreneurs alike. In countries such as the United States, databases from hospitals are being tapped for such purposes. On top of hospital databases, Singapore has a mandatory register for all lawful residents, where each is assigned a unique identifier: the identity card (IC) number. The IC number is used in almost all spheres of life, for example when consulting a healthcare professional. This means complete medical histories are available for each Singaporean. This leads us to the key questions:
- With these data sets, what questions can we ask and what are we already asking?
- How can Singapore translate Big Data into clinically relevant outcomes and make money from it?
- Is the individual at risk of having their privacy invaded for the better of society?
- Where are the largest life science commercial opportunities in Big Data over the next 5 years?
Join OBR-Singapore and our panel of experts as we explore the potential benefits and pitfalls of Big Data in the area of healthcare and the life sciences in Singapore.
6:30 – 7:00 PM Registration
7:00 – 7:10 PM OBR & Speaker Introduction
7:10 – 8:30 PM Panel Discussion and Q&A
8:30 – 9:30 PM Networking Reception
Prof. Low Cheng Ooi
Chief Medical Informatics Officer, Singapore Ministry of Health
Dr. Lee Ellen Drechsler
Director, R&D, Procter & Gamble Singapore
Dr. Shonali Krishnaswamy
Head, Data Analytics, Institute for Infocomm Research
A/Prof. Steve Rozen
Director, Duke-NUS Centre for Computational Biology
A/Prof. Teo Yik Ying
Head, , Biostatistics, Saw Swee Hock School of Public Health